OccuLogix Inc.

Dr. Michael A. Lemp is an acknowledged leader in the field of dry eye/ocular surface disease. Over the past three decades, Dr. Lemp has published 185 scientific articles and four books and served on national, international and government advisory boards. He organized and chaired the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eye; this report stands as the worldwide standard for the definition, classification and design of clinical trials for dry eye. His seminal work in the understanding of tear film instability in dry eye states has advanced the knowledge of pathological events in the disease process. After obtaining an MD degree and completing residency training from Georgetown, he served as a Fellow in Corneal Disease at the Massachusetts Eye and Ear Infirmary. In addition, Dr. Lemp worked at Schepens Eye Research Institute (Harvard Medical School) where he authored the initial papers on qualitative disorders of the tear film. He also served as Professor and Chairman of the Department of Ophthalmology at Georgetown University, as an officer and board member of many national and international ophthalmic organizations, member of the FDA Ophthalmic Devices Advisory Board, and NIH Study Sections and advisory committees. He is currently Clinical Professor of Ophthalmology at Georgetown and George Washington universities, Editor-in-Chief of The Ocular Surface – the international journal of review for ocular surface disease – and serves as a scientific advisor to many major ophthalmic pharmaceutical companies. Also, he is a scientific reviewer for all of the ophthalmic journals. Dr. Lemp has been a visiting professor at 68 universities and in 1998 received the Castroviejo Medal, the highest international prize for professional accomplishment in the field of corneal disease.

Mr. Walder, PA-C, 57, has over 30 years of experience of healthcare and management experience, both as a care giver and senior manager. Mr. Walder joined TearLab Corporation as Vice President of Operations in 2008. He is also a principal in The Samaritan Group, a consulting group specializing in medical services. Previously, he was the Vice President of Clinical Operations with Digirad, Corp., a leading developer of solid state gamma camera's and the largest provider of in-office cardiology imaging services. Prior to Digirad, Mr. Walder was the Business Unit Manager for Abbott Laboratories. Abbott Labs is a global organization that develops, manufactures and distributes healthcare products and pharmaceuticals. Mr. Walder graduated from California State College with a Bachelors in Electrical Engineering, the University of Southern California with a Baccalaureate in Medicine and the University of Phoenix with degrees in Business Administration and Management.

Steve Zmina is our Vice President of Manufacturing & Engineering. Steve has more than 28 years of product development experience in a number of high technology industries, including medical, telecommunications, semiconductor, industrial and high volume consumer products. His wide range of skills include product development, product marketing, manufacturing, and operation. Prior to TearLab Corporation, Steve was the Vice President of Product Development at Thermoscan, in San Diego, California, developing professional and consumer infrared ear thermometers. He has also been responsible for the development of a variety of high volume consumer products for Tandy Electronics. While at Tandy, his product development team developed over 40 new, high volume consumer products. He introduced digital signal processing into very low cost consumer products to significantly improve product performance and value to the customer. Steve has also held a number of other executive level positions in the semiconductor and power supply industries, developing products for the consumer and industrial markets. Steve has BSEE and MSEE degrees from Purdue University in semiconductor electronics.

Array

Michael Berg has over 25 years experience introducing new technology into the professional healthcare marketplace, through his own companies and as consultant to the industry. He is experienced in product development and acquisition, finance, manufacturing, marketing and strategic planning, domestic and international distribution, reimbursement and regulatory affairs. Michael, having studied and lived in Japan is an expert in Japanese regulatory and distribution strategies. As 50% joint–venture owner and President of HemoCue, Inc, Michael launched a blood hemoglobin point–of–care analyzer in the U.S. through a unique distribution model he created, the Independent Direct Distribution Organization. This model incorporated an educational approach to convert the healthcare profession from the prevailing spun microhematocrit technology, to a more expensive but accurate and safer hemoglobin test for the diagnosis of classic anemia. This distribution system provided all the advantages of a direct sales force at a fraction of the cost. Under this model, 13,000 HemoCue analyzers were sold into the market in the first 4 years of operation, with continued placement to date of 30,000+ instruments resulting in a business exceeding $50 million in annual revenue. Michael divested all interest in HemoCue, Inc. upon Mallinckrodt's acquisition of the parent company, HemoCue AB, in January 1991 for $100 million. As a consultant to the industry, Michael has repeatedly formulated and implemented successful strategies to obtain CLIA Waiver categorization for point–of–care technology, solicited and obtained CPT coding through the American Medical Association process, and facilitated strong reimbursement for his clients through the Medicare (CMS) system. Focused on market development and physician education, Michael is experienced in the design and coordination of clinical studies, positioning products to meet clinical guidelines, evidence–based medicine and pay–for–performance criteria, and co–promotion with the pharmaceutical industry to link diagnosis and therapy. Michael received his BA from the University of Notre Dame and currently resides in Orange County California.

Dr. Adrienne Graves is President and CEO of Santen Inc., the US subsidiary of Japanese-based Santen Pharmaceutical Co., Ltd. She joined Santen in 1995 and served as Senior Vice President, Worldwide Clinical Development. In that role, Dr. Graves was responsible for building a global team that successfully developed prescription products in ophthalmology, obtaining three FDA approvals in less than four years. She was appointed President and CEO in 2002. A visual scientist by training, Dr. Graves completed undergraduate work at Brown University and a Ph.D. at the University of Michigan. She completed a post-doctoral fellowship in visual neuroscience at the University of Paris and is fluent in French. Dr. Graves is the author/co-author of more than 30 scientific articles. In addition to her role as President and CEO of Santen Incorporated, she serves as a corporate officer for Santen Pharmaceutical Co., Ltd., and serves on the board of directors for OccuLogix, Inc. She also serves on the boards of the AAO (American Academy of Ophthalmology) Foundation, the Pan-American Association of Ophthalmology, and the Corporation Committee for the Brown University Medical School. She co-founded OWL (Ophthalmic Women Leaders) with Dr. Marguerite McDonald.

Daniel S. Durrie, M.D., is the leader of the refractive team at Durrie Vision in Overland Park, Kansas. With more than 25 years experience in refractive and corneal surgery, Dr. Durrie has been a pioneer in procedures to correct nearsightedness, farsightedness and astigmatism.Dr. Durrie has participated in 46 completed clinical studies and is presently an investigator or medical monitor for ten other studies. He has performed more than 40,000 refractive surgery procedures. Also, he has served as medical monitor for several excimer laser studies and has been an investigator for various others. He continues to review refractive surgical techniques and analyze clinical study data. Dr.Durrie trains surgeons from around the world on new surgical techniques. Dr. Durrie’s scientific articles and papers have appeared in numerous professional medical publications; he has been an author of more than100 peer-reviewed articles and book chapters. He serves on the Editorial Board for Ocular Surgery News (Section Editor), The Journal of Corneal and Refractive Surgery, Review of Ophthalmology, and Refractive Eyecare for Ophthalmologists. Dr. Durrie has given hundreds of presentations for professional organizations on four continents. Dr. Durrie received his medical doctorate and completed his residency at the University of Nebraska. He completed a Fellowship in corneal surgery at the Filkins Eye Clinic in Omaha. He is a board certified ophthalmologist and serves as Associate Clinical Professor and Directorof Refractive Surgery Services at the University of Kansas Medical Center. His honors include: one of the top 10 refractive surgeons in the nation, Ophthalmology Times;Best Doctors in America lists, multiple times; America’s Top Doctors;America's Top Ophthalmologist; Certified by the Council for Refractive Surgery Quality Assurance; Fellow, American Academy of Ophthalmology;Distinguished Lans Lectureship, International Society of Refractive Surgery, 1996; Pioneer in Refractive Surgery, 1999; Barraquer Lecturer,American Academy of Ophthalmology; Senior Achievement Award, American Academy of Ophthalmology, 2002; One of 50 Most Influential Ophthalmologists, 2005; and Lifetime Achievement Award, International Society of Refractive Surgery.

Array

An internationally recognized dry eye specialist, Professor Kazuo Tsubota has been focusing on the pathogenesis and treatment of dry eye.Dr. Tsubota is Chairman of the Department of Ophthalmology at Keio University School of Medicine, his alma mater. He was the first Japanese recipient of the American Academy of Ophthalmology Honor Awardin 1994. He heads a very large, active dry eye research group as well as the largest refractive group in Japan, which has several clinics throughout the country. Dr. Tsubota has many research projects underway which include ocular surface reconstruction, regeneration of the cornea, lacrimal gland,immunology of Sjogren’s disease and wound healing of refractive surgery. His personal interest is actively researching dry eye. He has written more than 250 peer-reviewed articles for publications includingNew England Journal of Medicine, The Lancet, Journal of Clinical Investigation, Journal of Immunology, FASEB Journal and The American Journal of Ophthalmology.In addition to holding editorial positions on three major ophthalmic journals, he is a regular reviewer for numerous international ophthalmic journals.

Dr. Bielory attended Lehigh University in Bethlehem, Pennsylvania,where he completed his BS in Engineering (Fundamental Science) and a Master’s in Molecular Biology (1976); M.D. degree from UMDNJ – NewJersey Medical School (1976-1980); Internal Medicine training at the University of Maryland Hospital; subspecialty training in Allergy and Immunology and Diagnostic Laboratory Immunology at the National Institutes of Health as a medical staff Fellow in the National Heart, Lung and Blood Institute and the National Institute of Allergy andInfectious Diseases, where his research focus has been on the classicimmune complex disorder – serum sickness. He was recruited back to his alma mater to direct the Division of Allergy and Immunology at the UMDNJ – New Jersey Medical School where, in addition to directing theonly training program in Allergy and Immunology in the state for 20years, he is presently Professor of Medicine, Pediatrics andOphthalmology, Director of Clinical Research and Development for the Department of Medicine, and Director of the UMDNJ Asthma and Allergy Research Center. Dr. Bielory has been consistently selected as one of New Jersey’s and New York’s “Top Docs” in metropolitan-area surveys for the past 15years. He has several hundred publications in peer-reviewed journals and serves on several editorial boards. He continues to serve invarious capacities in a variety of national organizations including asan Associate Editor of the Annals of Allergy, Asthma and Immunology;committee chairs for various committees in the American Academy of Allergy, Asthma and Immunology and the American College of Allergy,Asthma and Immunology; past Chairman of the NIH NHLBI Raynaud’sTreatment Trial; the program chairman for the ACAAI International Symposium on Complementary Interventions in Treatment of Asthma and Allergy; and reviewer for the NIH NCCAM Centers of Excellence forResearch on Complementary and Alternative Medicine (CERC). He has been appointed by the Governor of New Jersey to sit on the Clean Air Counciladvisory to the New Jersey Department of Environmental Protection. Dr.Bielory presently sits on the United States Pharmacopoeia (USP)Immunology and Respiratory Council of Experts and on the recently convened USP Medicare Model Committee mandated by the United Stated Congress.

Dr. Slade is a native Houstonian and is in private practice in Houston, Texas. He attended Tulane University and the University of Texas Medical School with a final, elective year spent at Guy's Hospital, London, graduating summa cum laude, with highest honors. He completed a residency at the Louisiana State University Eye Center in New Orleans and fellowships in corneal surgery at Baylor College of Medicine in Houston and in New York, New York on Project ORBIS. Dr. Slade is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. He is an active teacher of surgical techniques and has taught and certified over 8,000 surgeons LASIK and lamellar refractive surgery. In 1991, along with Stephen Brint, M.D., he performed the first LASIK in the United States. Later he performed the first Custom LASIK ablation based on topography in the United States, and has since completed tens of thousands of cases. Dr. Slade has remained on the cutting edge, having the nation's first and longest experience with all laser LASIK, accommodating iols (crystalens) and implantable corneal contact lens. He has received numerous awards and has produced many articles, book chapters, holds four patents or patents pending in the field and has authored five textbooks on refractive surgery. He has been featured in numerous news segments aired on CBS, ABC and PBS and was the featured surgeon on the Emmy Award winning PBS documentary "20/10 by 2010?" narrated by Walter Cronkite.